Enhancing Knowledge Implantable Cardioverter-Defibrillators (ICDs)
The specific aims of the patient intervention are to:
- increase patient knowledge about pacemakers (PM) and implantable cardioverter-defibrillators (ICDs)
- help patients to identify if their PM or ICD has been interrogated
- improve patient's physician-patient communication skills
- teach patients how to identify if their device has been recalled
- train patients what to do in case of a device recall
The educational interventions proposed, if proven to be effective by this pilot, will provide a low-cost, reproducible intervention to improve the clinical care and safe management of pacemakers (PM) and implantable cardioverter-defibrillators (ICD) in patients. The goal of the intervention will be to promote the safe use of implantable pulse generators.
|Pacemaker Implantable Cardioverter-Defibrillators||Other: Questionnaires Other: Phone Interviews Behavioral: Educational Packet|
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Patient Knowledge of Pacemaker/Implantable Cardioverter-Defibrillator-Phase II|
- Patient knowledge about pacemakers (PM) and implantable cardioverter-defibrillators (ICDs) [ Time Frame: Total knowledge score evaluated at baseline and at 2-month and 4-month post educational intervention. ]
|Study Start Date:||January 2009|
|Study Completion Date:||January 2015|
|Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Patient Knowledge Assessments
Questionnaires + Phone Interview
3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
Other Name: SurveyOther: Phone Interviews
2 follow-up phone interviews.Behavioral: Educational Packet
Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
If you agree to take part in this study, you will complete 3 sets of questionnaires (at the beginning of the study, at 2-months and at 4-months) which will be sent to you and returned by you through the mail. This will not require you to travel to M.D. Anderson. In addition to the questionnaires, you will also complete 2 follow-up phone interviews.
The first set of questionnaires will be mailed to your home. The questionnaires will ask questions about your anxiety level and how much you know about pacemakers or implantable cardioverter-defibrillators. There will also be questions about your gender, age, ethnicity, and race. The questionnaires will take about 25 minutes to complete. When you are finished, you will mail the questionnaires to the study staff. An envelope with pre-paid postage will be provided.
After you have completed the questionnaires, you will receive an educational packet in the mail. The packet will have a DVD or a video (depending on whether you tell us you have a DVD player or a VHS player) with information on medical devices, device recall information (when and why certain devices have been recalled in the past), a list of on-line resources and benefits of routine follow-up.
The study staff will call your home 1 week after you receive the educational packet for a follow-up interview. A member of the study staff will review the packet with you. The phone call will last about 20 minutes.
Approximately 2 months and at 4 months after you complete the first set of questionnaires, an additional set of questionnaires will be mailed to you. You will be asked to complete the same questionnaires as you did in the first set. At 4 months an additional questionnaire about the information in the educational packet and how useful it was to you will be included. The questionnaires will take about 25 minutes to complete. When you are finished, you will mail the questionnaires to the study staff. An envelope with pre-paid postage will be provided.
Length of Study:
You participation on this study is complete once you have completed the additional questionnaires.
This is an investigational study. Up to 104 patients will be enrolled in this study. All will be enrolled at M. D. Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00822965
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Maria Suarez-Almazor, MD, PhD||M.D. Anderson Cancer Center|